Tagraxofusp for Post-Transplant Maintenance
Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelofibrosis and Chronic Myelomonocytic Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 44 patients (estimated)
- Sponsors
- University of Virginia
- Tags
- CD123, Maintenance, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 2125
- NCT Identifier
- NCT05233618
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.